ImmunoGen, Inc. Announces Oppenheimer 26th Annual Healthcare Conference Webcast
December 02 2015 - 1:00PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that David Johnston,
Executive Vice President and Chief Financial Officer, will present
at the upcoming Oppenheimer 26th Annual Healthcare Conference. The
presentation is scheduled for 2:45 pm ET on December 9, 2015.
This webcast will be accessible live through the "Investors"
section of the Company's website, www.immunogen.com; a replay
will be available at the same location for approximately a
week.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company's lead product candidate, mirvetuximab
soravtansine, is a potential treatment for folate receptor
α-positive ovarian cancer and other solid tumors. A number of major
healthcare companies have licensed limited rights to use
ImmunoGen's ADC technology to develop anticancer therapies; it is
used in Roche's marketed product, Kadcyla®. More information about
the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151202005105/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024